Contexa
Investors

The record layer that follows the person.

Health systems have digitised the provider. Nobody has digitised the patient's own account of their life, and every attempt so far has started from monitoring rather than ownership.

4.3m

Australians had a mental disorder in the last 12 months, 21.5% of adults

$220b

annual cost of mental ill health and suicide to Australia, around $600m a day

~46,000

registered psychologists, growing 4.1% a year, at 172 per 100,000 people

under half

of those with a 12 month disorder sought any treatment at all

ABS National Study of Mental Health and Wellbeing 2020–22 · Productivity Commission Inquiry into Mental Health 2020 · Psychology Board of Australia, November 2024

Thesis

Ownership is the defensible position.

Three structural bets, each of which gets stronger rather than weaker as the category matures.

One

Portability beats integration

Interoperability projects have been failing for two decades because they require institutions to cooperate. A record owned by the person moves between services without any of them agreeing to anything.

Two

Trust compounds

The value of the record is the honesty of what is in it, and honesty depends entirely on the person believing nobody is watching. Every competitor that adds monitoring degrades their own dataset. We cannot follow them there, and that is the point.

Three

The clinician is the channel

Consumer health apps burn money on acquisition and lose people in weeks. Contexa arrives through a service the person already attends, with a clinician who benefits directly from them using it.

Model

Services pay. People do not pay for their own record.

Indicative structure. Pricing is being tested through the pilot rather than assumed.

SegmentWho buysWhy they buyShape
Private practicesPractice principalBetter prepared sessions, less time reconstructing history, a differentiator for clientsPer clinician, per month
Community servicesProgramme or service managerContinuity across a caseload with high turnover, and outcome evidence for funding renewalPer seat, annual
Primary Health NetworksRegional commissionerContinuity between commissioned services that do not share systemsProgramme licence
IndividualsThe personTheir own record, kept when they leave any serviceFree, permanently

The free individual tier is not a growth tactic, it is the thesis. A record a person loses when they stop paying is not a record they own, and the whole argument collapses.

Where we are

Stage and what is next

A working prototype of both sides

Person's app and practice portal, sharing one record. You can open it from this page, change something on one side and watch it appear on the other. Nothing is in clinical use and there are no users yet.

Design and policy groundwork

Consent architecture, clinical safety policy, privacy impact assessment and clinician training drafted, and built into the prototype rather than sitting beside it as documents.

Next: build to production

Two engineers, roughly six months, to take the prototype to something a practice can safely use. This is what the raise funds first.

Then: clinical pilot, then expansion

The test is specific and falsifiable. After four weeks, do people report feeling more prepared and more accurately understood, and does clinician reading time stay under the time it saves. If the answers are no, we would rather find out early and cheaply.

What we are not claiming

No users, no revenue, no pilot data and no outcome evidence yet. Every figure about how the product performs is a target we intend to be measured against, not a result. What exists is a prototype detailed enough that the design decisions are real and testable.

Risks

What could go wrong, stated by us first

You will find these anyway. We would rather you heard our answer alongside them.

Clinician adoption

Risk. Clinicians reject anything that adds minutes.
Answer. Summaries arrive pre-approved rather than raw, and reading time is a headline metric we track and would act on.

Engagement decay

Risk. Self-tracking apps lose half their users in a month.
Answer. The check-in exists to serve an appointment the person already has, which is a reason to keep going that a mood tracker does not have.

Regulatory drift

Risk. One feature turns this into a regulated medical device.
Answer. The line is explicit in the product: no scoring, no triage, no treatment direction. Crossing it is a decision with governance work attached, not an accident.

Misuse

Risk. Supporter features weaponised in a controlling relationship.
Answer. Designed against from day one, and covered in mandatory clinician training. It is a permanent risk to manage rather than a bug to close.

Incumbents

Risk. A practice management vendor bolts on a client diary.
Answer. They can build the feature. They cannot make the record belong to the person without dismantling the model their customers pay for.

Trust, once

Risk. A single privacy failure ends the company.
Answer. Correct, and we treat it that way. It is why there is no data sale, no model training and no monitoring, even where those would be commercially convenient.

The ask

$350,000 pre-seed, twelve months

To a production build, a completed independent privacy assessment, and a measured pilot with evidence at the end. Not to a bigger team or a longer runway.

Use of fundsAmount
Build
Fixed price delivery with an established engineering partner, using the prototype as the specification
$120k
Clinical lead
Part time psychologist with the authority to stop a feature, appointed before the build starts
$50k
Compliance and security
Independent privacy impact assessment, penetration test, legal, terms and insurance
$60k
Pilot and evaluation
Implementation support, clinician time and an independent evaluation partner
$50k
Hosting and operations
Australian hosting, monitoring, app store and tooling for twelve months
$15k
Contingency
Roughly fifteen percent, because something always costs more than the quote
$55k
Total$350k

What it buys

  • A production build a practice can safely use
  • A completed independent privacy assessment
  • A pilot across a small number of practices
  • An answer to the four week test, either way

Who we are looking for

  • Investors comfortable with a clinical evidence timeline
  • Operators who have sold into health services
  • Introductions to Primary Health Networks and community programmes
  • Clinical advisors, especially psychiatry
  • People who will argue with the privacy model rather than nod at it

The full deck

Fourteen slides covering the problem, the product, the thesis, pricing, the risks and this ask. No form in front of it.